Phase I-III Clinical Trials
Sequential human drug trials assessing safety, dosing, efficacy, and comparative benefit before regulatory approval.
Core metadata
- ID: phase_i_iii_clinical_trials
- Era: Modern
- First known date: 1968 (decade)
- Region: United States, Europe, and global clinical research
- Review status: source_checked
- Maturity: established
Prerequisites
- Adverse Event Reporting Systems (adverse_event_reporting_systems)
- Double-Blind Clinical Trials (double_blind_clinical_trials)
- Pharmacokinetics and Pharmacodynamics (pharmacokinetics_pharmacodynamics)
Dependents
- Immune Checkpoint Inhibitors (immuno_oncology_checkpoint_inhibitors)
- Regulatory Drug Approval (regulatory_drug_approval)
Fields
Field lanes
- Pharmaceuticals & Drug Development: Clinical Development & Regulation
Node sources
- The Drug Development Process (U.S. Food and Drug Administration, 2026, official_agency) • Supports: node, maturity
- ClinicalTrials.gov Glossary (ClinicalTrials.gov, 2026, official_agency) • Supports: node, maturity
Prerequisite edge evidence
Edge/source evidence summary:
- Prerequisite edges: 3
- Average edge confidence: 68%
- Prerequisite sources: 3
- expert_inference: 3
| Prerequisite | Type | Confidence | Evidence level | Note | Sources |
|---|---|---|---|---|---|
| Double-Blind Clinical Trials (double_blind_clinical_trials) | enabling | 68% | expert_inference | Double-Blind Clinical Trials provides a capability that enables this technology without being the only possible path. |
|
| Pharmacokinetics and Pharmacodynamics (pharmacokinetics_pharmacodynamics) | enabling | 68% | expert_inference | Pharmacokinetics and Pharmacodynamics provides a capability that enables this technology without being the only possible path. |
|
| Adverse Event Reporting Systems (adverse_event_reporting_systems) | enabling | 68% | expert_inference | Adverse Event Reporting Systems provides a capability that enables this technology without being the only possible path. |
|
This page is generated from canonical era JSON and is indexable by URL.